Benitec Biopharma Inc

+0.30 (+7.61%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)20.43M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.04 Million
Adjusted EPS-$0.75
See more estimates
10-Day MA$4.38
50-Day MA$4.58
200-Day MA$4.03
See more pivots

Benitec Biopharma Inc Stock, NASDAQ:BNTC

3940 Trust Way, Hayward, California 94545
United States of America
Phone: +1.510.780.0819
Number of Employees: 14


Benitec Biopharma, Inc. is a development-stage biotechnology company, which focuses on the advancement of novel genetic medicines. The firms proprietary platforms includes DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on April 13, 2020 and is headquartered in Hayward, CA.